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Background: Atrial fibrillation (AF) is commonly managed by a variety of specialists. Current guidelines differ in
their recommendations leading to uncertainty regarding important clinical decisions. We sought to document
practice pattern variation among cardiologists, emergency physicians (EP) and hospitalists at a single academic,
tertiary-care center.
Methods: A survey was created containing seven clinical scenarios of patients presenting with AF. We analyzed
respondent choices regarding rate vs rhythm control, thromboembolic treatment and hospitalization strategies.
Finally, we contrasted our findings with a comparable Australasian survey to provide an international reference.
Results: There was a 78% response rate (124 of 158), 37% hospitalists, 31.5% cardiologists, and 31.5% EP. Most
respondents chose rate over rhythm control (92.2%; 95% CI, 89.1% - 94.5%) and thromboembolic treatment (67.8%;
95% CI, 63.8% - 71.7%). Compared to both hospitalists and EPs, cardiologists were more likely to choose thromboembolic
treatment for new and paroxysmal AF (adjusted OR 2.38; 95% CI, 1.05 - 5.41). They were less likely to favor hospital
admission across all types of AF (adjusted OR 0.36; 95% CI, 0.17 - 0.79) but thought cardiology consultation was more
important (adjusted OR 1.88, 95% CI, 0.97 - 3.64). Australasian physicians were more aggressive with rhythm control for
paroxysmal AF with low CHADS2 score compared to US physicians.
Conclusions: Significant variation exists among specialties in the management of acute AF, likely reflecting a lack of
high quality research to direct the provider. Future studies may help to standardize practice leading to decreased rates
of hospitalization and overall cost.Background
Atrial fibrillation (AF) is the most common arrhythmia
encountered in clinical practice, affecting an estimated 5
million adults in the US in 2000 [1] with its prevalence
predicted to more than double by 2050 [1,2]. The in-
creasing pervasiveness of AF has been accompanied by
increased emergency department (ED) visits [3,4], hospi-
talizations, and rising healthcare costs. Total national
incremental costs for treatment of AF were estimated at
US$26 billion in 2008, including US$16.4 billion for hos-
pitalizations (63%) [5].
There are diverse management strategies available for
the treatment of AF. Current consensus guidelines
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unless otherwise stated.(ACC), American Heart Association (AHA), American
College of Chest Physicians (ACCP), and European Soci-
ety of Cardiology (ESC) vary in their recommendations
and are particularly ambiguous in regards to manage-
ment in the acute setting [6,7], largely because high
quality studies comparing different management strat-
egies are lacking. Variation regarding management
decisions such as selecting rate vs rhythm control, tim-
ing and need for thromboembolic treatment, as well as
cardiology consultation and indications for hospitalization
all result in disparate care of patients.
To our knowledge, practice variation among physi-
cians who commonly manage acute presentations of AF
has not been evaluated in the US. To address this gap,
we designed a survey to (1) document differences in
practice patterns in the management of acute presenta-
tions of AF between specialties; (2) identify specific areas
of management that remain controversial; and (3) contrasthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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international study performed in Australia and New
Zealand.Methods
Recruitment and setting
All faculty members in the Academic Hospitalist
Program, the Division of Cardiovascular Medicine, and
Department of Emergency Medicine at a single tertiary
academic teaching hospital were invited to participate in
an online survey in February 2012 via an email contain-
ing a link to the web-based questionnaire. The survey
was closed 30 days later. Reminder emails were sent 1
and 3 weeks after the initial invitation and respondents
were incentivized with the possibility of winning a nom-
inal reward. The University of Michigan Medical School
Institutional Review Board approved this study.Survey development and content
The survey contained 7 hypothetical scenarios of pa-
tients presenting to the ED with common presentations
of acute AF (Table 1). The entire survey is available in
Additional file 1: Appendix A. Each case included the
patient’s age, presenting symptoms with duration, pertin-
ent past medical history, physical examination findings,
CHADS2 score, and the results of relevant diagnostic test-
ing. CHADS2 score was used instead of CHA2DS2-VASc
in order to be able to directly compare specific scenarios
between the US and Australasian surveys as there was not
enough information provided in the Australasian scenarios
regarding history of vascular disease to calculate a
CHA2DS2-VASc score. Additionally, at the time that this
survey was administered, international guidelines still sug-
gested using CHADS2 for stroke risk calculation [6,8,9].
The survey was developed with a 1:1 ratio of scenarios as
opposed to attempting to mirror the epidemiology of vari-
ous presentations of AF in an ED population. This design
choice was in line with our objective to describe variation
in physician behavior across distinct clinical scenarios; ourTable 1 Clinical scenarios presented in survey
Scenario Age Type AF Duration
1 56 New <48 hou
2 78 New < 48 hou
3 50 New ≥ 48 hou
4 77 New ≥ 48 hou
5 54 Paroxysmal < 48 hou
6 76 Paroxysmal < 48 hou
7 82 Chronic < 48 hou
NOTE: All patients had normal kidney function, no history of structural heart disease
not taking any previous cardiac medications.
Low CHADS2 score ≤ 1. Abbreviation: AF atrial fibrillation.objective was not to make overall descriptive statements
about the target physician population.
The questions following the scenarios explored choice
of 1st line therapy aimed at rate or rhythm control and
decisions regarding thromboembolic treatment. Antico-
agulants include aspirin, warfarin, dabigatran, and rivar-
oxaban (apixaban was not yet approved for use at the
time of survey distribution). Antithrombotics include
unfractionated and low-molecular weight heparins.
Stand-alone questions explored need for cardiology
consultation and hospitalization. The questions were
accompanied by fixed possible responses, but most con-
tained an “other” and a free-text option. Information
entered in free-text form was coded according to exist-
ing categories if possible or “other.” Demographic infor-
mation including age, gender, years in practice, field of
training, and volume of experience was also collected.
All answers were non-identifying and respondents had
the choice of not providing demographic information.
The survey was developed in collaboration with
specialists in survey methodology in the Department
of Biostatistics at the School of Public Health and the
Institute for Social Research at the University of
Michigan. The questionnaire was pre-tested by 9 physi-
cians in training not participating in the study across the
same 3 departments and feedback was used to improve
the final survey.
Statistical analysis
Categorical data were summarized using frequencies (%)
and their associations were analyzed using chi-square
tests. To analyze predictors of choosing a rate control
strategy and choosing thromboembolic management,
multivariable logistic regression analyses were performed
using specialty, type of AF (new diagnosis, paroxysmal,
or chronic), CHADS2 score (low = 0 or 1, high ≥ 2), dur-
ation of AF (< or ≥ 48 hours), length of time physician
has been in practice (≤5 or > 5 years), frequency with
which physician encounters acute AF (< once per week
or at least once per week), and use of guidelines (ACC,of symptoms CHADS2 Score On warfarin
rs Low No
rs High No
rs Low No
rs High No
rs Low No
rs High Yes
rs High Yes
, recent negative stress test, no contraindications to anticoagulation, and were
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Heart Rhythm Society) as predictor variables. Adjusted
odds ratios (OR) with corresponding 95% confidence
intervals (95% CI) were calculated for each predictor.
Repeated measurements on each physician (across the
different scenarios) were accommodated using linearized
estimates of standard errors that adjusted for the non-
independence of responses introduced by clustering of
responses within a physician.
Models of disposition decisions and need for cardi-
ology consultation were also estimated, considering the
3 possible scenarios (new-onset, paroxysmal, and
chronic AF). Multivariable logistic regression analyses
were performed predicting likelihood to admit and likeli-
hood to consult cardiology adjusting for clustering
within any given physician. Predictors in these models
included specialty, length of time physician has been in
practice, frequency with which physician encounters
acute AF, and use of guidelines as above. Adjusted ORs
with corresponding 95% CI were calculated.
Finally, we compared practice patterns of these US
physicians with those of Australasian physicians docu-
mented in a similar survey [10] of EPs and cardiologists.
This comparison was planned a priori but our survey in-
cluded newly available oral anticoagulants and did not
seek to measure best practice measures. Three scenarios
in each survey were identified as equivalent based on
type of AF, duration of presenting symptoms, andTable 2 Demographic characteristics of respondents
Characteristic Cardiologists Emerg
n(%) n(%)
Age
<40 11 (28) 14 (36
≥40 18 (46) 17 (44
Missing 10 (26) 8 (21)
Male 25 (64) 24 (62
Missing 10 (26) 8 (21)
Years of practice
≤5 11 (28) 13 (33
>5 19 (49) 18 (46
Missing 9 (23) 8 (21)
AF experience
≥ once per week 12 (31) 29 (74
< once per week 18 (46) 3 (8)
Missing 8 (21) 7 (18)
Use of guidelines
Yes 30 (77) 22 (56
No 0 10 (26
Missing 9 (23) 7 (18)CHADS2 score. The responses to our questionnaire
were recoded to be consistent with the data presented in
the Australasian survey and new frequencies were calcu-
lated. In the absence of the individual survey responses
for the Australasian survey, we viewed the Australasian
response distributions as fixed population parameters
and performed one-sample chi-square goodness of fit
tests for each equivalent pair of scenarios.
Differences were considered statistically significant at
p < 0.05. All statistical analyses were performed using
the Stata software (Version 13.0).
Results
There was a 78% (124/158) response rate to the online sur-
vey invitation; 31.5% of the respondents were cardiologists,
31.5% were EPs, and 37% were hospitalists. Table 2 depicts
the demographic characteristics of the respondents.
Rate versus rhythm strategies
As illustrated in Figure 1, the majority of respondents
among all specialties selected rate over rhythm control
as their 1st line treatment across all scenarios (92.2%;
95% CI, 89.1% to 94.5%) with diltiazem being the most
preferred agent (78%) followed by metoprolol (14%).
When a rhythm control strategy was selected, DCCV
was most common overall with 21 respondents selecting
it as 1st line therapy (5%). Interestingly, DCCV was the
only rhythm control strategy employed by EPs andency physicians Hospitalists p-value
n(%)
0.24
) 24 (52)
) 10 (22)
12 (26)
) 18 (39) 0.033
11 (24)
0.897
) 17 (37)
) 18 (39)
11 (24)
0.001
) 23 (50)
12 (26)
11 (24)
0.024
) 27 (59)
) 8 (17)
11 (24)
Figure 1 1st choice management options selected by >1% respondents. Stacked bar graph depicting the percentage of each specialty that
selected Diltiazem, Esmolol, DCCV, or Metoprolol as 1st line management across all scenarios. NOTE: Other choices in the survey not represented
in the graph included: Digoxin, Verapamil, Amiodarone, Ibutilide, Procainamide, Propafenone, and Other. There was a significant difference between
specialties regarding 1st choice management across all scenarios, p = 0.032. Abbreviation: DCCV, direct current cardioversion.
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agents such as amiodarone, ibutilide, or propafenone (all
chosen by < 1% of respondents). In multivariable model-
ing, the adjusted odds of choosing rate control were
higher with AF ≥ 48 hours compared to < 48 hours (OR
6.27, 95% CI 2.35 to 16.74) and higher with chronic AF
compared with new diagnosis AF (OR 3.09, 95% CI 1.04
to 9.15). Specialty, CHADS2 score, experience with AF,
years in practice, and use of current guidelines were not
independent predictors of choosing rate control.
Thromboembolic treatment decisions
Most respondents chose thromboembolic treatment
across all scenarios (67.8%; 95% CI 63.8% to 71.7%),
though with significant differences among specialties0
10
20
30
40
50
60
70
80
90
100
US Cardiologists Australasian
Cardiologists
p = 0.0005
Figure 2 Thromboembolic treatment. Bar graph depicting the percentag
percentage that chose bridging in the acute management of AF across scena
the decision to use thromboembolic treatment, p = 0.014 as well as the decisregarding the decision (Figure 2). Cardiologists were
more likely to do so in new and paroxysmal AF scenar-
ios than either of the other specialists (OR 2.38, 95% CI
1.05 to 5.41). They were also more likely to choose
transesophageal echocardiogram (78.8% vs 69.5% of hos-
pitalists and 57.6% of EPs, p = 0.01) and use antithrom-
botics (90.4% vs 87.4% of hospitalists and 7.2% of EPs, p
< 0.001) prior to cardioversion. In multivariable model-
ing, the adjusted odds of choosing thromboembolic
treatment were higher with a high CHADS2 score (OR
6.89; 95% CI 3.79 to 12.56). A low CHADS2 score and
duration of AF < 48 hours predicted a lower odds of
bridging (defined as administration of short-acting hep-
arin for antithrombosis until warfarin levels become
therapeutic) (OR 0.34, 95% CI 0.17 to 0.68 and OR 0.59,US EPs Australasian EPs
Aspirin
Warfarin
Heparin
None
Other
p = 0.8158
e of each specialty choosing thromboembolic treatment and the
rios 1–5. There was a significant difference between specialties regarding
ion to bridge, p < 0.001. NOTE: Abbreviation: AF, atrial fibrillation.
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thromboembolic treatment selected a regimen of hep-
arin with subsequent warfarin. EPs used heparin without
subsequent long-term anticoagulation the most and
avoided newer generation anticoagulants such as dabiga-
tran and rivaroxaban (agents available at the time of the
survey distribution) altogether. Hospitalists were more
likely than EPs or cardiologists to use warfarin or aspirin
alone (36.5%, 9.6%, and 12.9%, respectively). In multivar-
iable modeling, cardiologists and EPs had 4 times higher
odds of choosing to bridge than hospitalists (OR 4.02,
95% CI 1.67 to 9.65).
Admission and consultation decisions
The overwhelming majority of respondents in all special-
ties agreed that scenarios of new presentations of AF0
10
20
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70
80
90
100
New AF Paroxysmal AF
*
0
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80
90
100
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*
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b
Figure 3 Likelihood to Admit and Need for Cardiology Consultation.
to admit in scenarios of new vs paroxysmal vs chronic AF. There was a signific
AF (p < 0.044). Abbreviation: AF, atrial fibrillation. b: Need for Cardiology Consult
thought a cardiology consult would be necessary for scenarios of new vs paro
consultation between specialties for new onset AF (p = 0.023). Abbreviation: A(89.7%) required admission (Figure 3a). Cardiologists
were least inclined to admit all types of AF (OR 0.36;
95% CI 0.17 to 0.79) and EPs most often favored admis-
sion. Specifically, EPs had 15.2 (95% CI 1.26 to 183.73)
fold higher odds of admitting cases of new presentations
of AF compared to cardiologists. More frequent expos-
ure to AF was associated with a decreased odds of
admitting patients in scenarios of new diagnosis AF (OR
0.08; 95% CI 0.01to 0.65) but did not bear any signifi-
cance on decisions for admitting other types of AF.
All specialists believed cardiology consultation was less
important for scenarios of paroxysmal AF (OR 0.46; 95%
CI 0.31 to 0.70) and chronic AF (OR 0.12; 95% CI 0.06
to 0.25) compared to new-onset AF (Figure 3b). Despite
the fact that cardiologists were least in favor of admit-
ting this patient population, they thought they should beChronic AF
Cardiologists
Emergency Physicians
Hospitalists
Total
* p < 0.044
Chronic AF
Cardiologists
Emergency Physicians
Hospitalists
Total
* p = 0.023
a: Likelihood to Admit. Bar graph comparing percentages of likelihood
ant difference in admitting practices between specialties for paroxysmal
ation. Bar graph comparing the percentage of each specialty that
xysmal vs chronic AF. There was a significant difference in need for
F, atrial fibrillation.
Funk et al. BMC Cardiovascular Disorders  (2015) 15:21 Page 6 of 9consulted in the management of these patients more so
than their colleagues (OR 1.88; 95% CI 0.97 to 3.64).
International comparison
The most significant differences in the international
comparison were noted in a scenario of paroxysmal AF
with symptoms < 48 hours and a low CHADS2 score.
Australasian physicians were more aggressive with
rhythm control strategies as a 1st line treatment option
compared with our physicians (Figure 4) and use of
thromboembolic treatment also differed significantly
(Figure 5a). Qualitatively, 34% of Australasians chose as-
pirin while none of their US counterparts did.
For the other two comparable scenarios (both new
AF ≥ 48 hours, but one with low and the other with high
CHADS2 score), rate control was the preferred 1st line
agent by both groups. In the high CHADS2 score sce-
nario, no US physicians chose to anticoagulate with
either aspirin or warfarin without bridging, but 26% of
Australasian EPs and 8% of cardiologists chose aspirin
and 46% of EPs and 84% of cardiologists chose warfarin
without bridging. The vast majority of US cardiologists
(85%) and EPs (89%) chose heparin therapy. In the low
CHADS2 score scenario (Figure 5b), there was signifi-
cant disagreement regarding thromboembolic treatment.
All Australasian cardiologists chose some agent for
stroke prevention as opposed to the nearly 1/3rd of their
US counterparts who chose none. Qualitatively, 25% of
Australiasian EPs chose warfarin alone while none of the
US EPs did.
Discussion
To our knowledge, this is the first study to evaluate
practice pattern variation among specialists whoFigure 4 Australasian versus US Comparison of Rate vs. Rhythm Control
Bar graph comparing percentages of rate vs rhythm control as 1st line manag
low CHADS2 score. Australasian cardiologists and EPs were more aggressive w
Abbreviations: AF, atrial fibrillation; EP, emergency medicine physicians; US, Unfrequently encounter acute AF at a single center in the
US. The vast majority (92%) of respondents chose rate
over rhythm control for acute management of AF. This
was in stark contrast to Australasian counterparts who
overwhelmingly chose rhythm control strategies. Add-
itionally, there was a high degree of variability among
US specialists in the determination of need and type of
thromboembolic treatment. Lastly, we observed substan-
tial disagreement among the specialists regarding need
for hospital admission and cardiology consultation.
Such international variation in rate vs rhythm control
has been documented in other investigations as well. In
an international survey of EPs, 94% of US physicians first
attempted rate control compared with 70.7% of
Canadians, 61.1% of Australasian, and 43.1% of those in
the UK [11]. The issue of rate vs rhythm control in the
acute management of AF remains unsettled. Several
studies suggest a potential benefit of early and aggressive
rhythm control in the acute setting [12-17]. A Canadian
study of 660 patients by Stiell et al. looked at the efficacy
and safety of the Ottawa Aggressive Protocol which
treats low risk AF patients with procainamide followed
by DCCV if necessary in the ED [18]. They reported a
93.3% conversion rate with 98.6% of patients discharged
from the ED. Aggressive ED rhythm management re-
sulted in significant overall hospital savings of tens of
thousands of dollars [19], raising the possibility that such
strategies may result in fewer hospital admissions and
decreased overall cost.
Determination of the timing and need for thrombo-
embolic treatment exhibited the most noteworthy vari-
ability in reported practice across physician specialties
within our center and internationally, echoing what has
been reported by others [20,21]. The confusion isStrategies in Paroxysmal AF < 48 hours with Low CHADS2 Score.
ement for a scenario of paroxysmal AF with symptoms <48 hours and
ith rhythm control strategies as compared with US counterparts.
ited States.
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Figure 5 Australasian versus US comparison in thromboembolic treatment decisions. a: Australasian versus US Comparison in Thromboembolic
Treatment Decisions for Scenarios of Paroxysmal AF < 48 hours with Low CHADS2 Score. US cardiologists more often chose no thromboembolic treatment,
fewer used aspirin, and more selected heparin or other strategies compared to their Australasian counterparts. The category “Other” included
Australasian survey responses of clopidogrel, US responses of dabigatran and rivaroxaban, as well as, write-in responses in both surveys.
Abbreviations: AF, atrial fibrillation; EP, emergency medicine physicians; US, United States. b: Australasian versus US Comparison in Thromboembolic
Treatment Decisions for Scenarios of New Onset AF≥ 48 hours with Low CHADS2 Score. There were significant differences among both physician groups.
US cardiologists chose no thromboembolic treatment and heparin more often, and used aspirin and warfarin alone less often than their Australasian
colleagues. US EPs more often selected not to use thromboembolic treatment compared to their Australasian counterparts, and selected aspirin and
heparin less frequently. Abbreviations: AF, atrial fibrillation; EP, emergency medicine physicians; US, United States.
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ommendations provided by various guidelines regarding
care for those patients with AF duration < 48 hours. The
Canadian Cardiovascular Society AF guidelines [9] rec-
ommend only aspirin use in conjunction with a rhythm
control strategy in those with CHADS2 score of 0, oral
anticoagulants for those with CHADS2 scores ≥ 1, and
antithrombotic use based on CHADS2 score if cardio-
version was successful. The ACCP recommends heparin
use prior to elective cardioversion or a TEE-guided ap-
proach [6]. The newest ACC/AHA/HRS guidelines [7]
recommend that antithrombotics be initiated eitherbefore or immediately after cardioversion in those with
high risk of stroke (CHA2DS2-VASc score ≥2) with sub-
sequent long- term anticoagulation. Regarding low-risk
patients, they recommend anticoagulation (but no
antithrombotics) for the cardioversion itself and no
post-cardioversion anticoagulation, a departure from
2006 recommendations [8]. These inconsistencies reflect
the fact that no randomized controlled trials comparing
thromboembolic treatment strategies in patients with
acute AF exist. As decisions regarding thromboembolic
treatment become more complex with the introduction
of several new oral anticoagulants approved for stroke
Funk et al. BMC Cardiovascular Disorders  (2015) 15:21 Page 8 of 9risk reduction in non-valvular AF, determining the
appropriate evidence-based guidance to support provider
decision-making in the acute management of AF is
critical [22].
Limitations
This was a single academic-center study; our findings
therefore may not be representative of practice patterns
at other academic, community or smaller US hospitals
but instead reflect our institution’s experience. Also,
although scenarios were made to represent common
clinical presentations of acute AF with extensive clinical
details provided, we cannot be certain that responses re-
flect real life practice and that all pertinent information
clinicians use to make decisions was available for each
scenario. Attempts were made to minimize these con-
founders with the pilot survey. Additionally, there may
be an undetected nonresponse bias in our results, given
that survey responses were anonymous and we did not
have a sampling frame that included demographic infor-
mation for all physicians. An external population data
resource would be needed to determine how closely
aligned our survey respondents were with the true popu-
lation demographics, and to our knowledge, such a
resource does not exist for the target physician popula-
tion of interest. This makes it impossible to know
whether the demographic distribution varied between
respondents and non-respondents. However, given the
high response rate (78%) to our survey, this would seem
to be unlikely. Finally, there was a substantial time be-
tween our survey and the 2010 Australasian survey, and
our survey was not specifically developed for direct
comparison to the Australasian survey, although many
of the scenario based questions had substantial overlap
to allow a basis for evaluation.
Conclusion
As the prevalence of AF increases and more patients are
treated for acute exacerbations in the ED setting, there
will be a need for population-level data on the manage-
ment and outcomes of ED patients with AF in order to
improve delivery of care. Based on a survey of cardiolo-
gists, EPs, and hospitalists we demonstrated a high
degree of practice pattern variation in the management
of acute presentations of AF regarding 1st line agents
used in rate and rhythm control strategies, decisions
regarding thromboemolic treatment, and need for cardi-
ology consultation and hospitalization. The degree of
variation noted within our own institution likely reflects
a lack of high quality observational and interventional
research to help direct the provider. Optimizing the
management of acute AF could lead to substantial cost
savings if unnecessary testing, interventions, and hospi-
talizations can be avoided.Additional file
Additional file 1: Acute Management of Recent-Onset Atrial Fibrillation
and Flutter Survey.
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